Morgan Stanley G1 Therapeutics, Inc. Call Options Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GTHX
# of Institutions
54Shares Held
11MCall Options Held
1.85MPut Options Held
1.18M-
Black Rock Inc. New York, NY3.08MShares$22 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA1.36MShares$9.74 Million0.03% of portfolio
-
D. E. Shaw & Co., Inc. New York, NY767KShares$5.48 Million0.0% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ464KShares$3.31 Million0.0% of portfolio
-
Tekla Capital Management LLC424KShares$3.03 Million0.04% of portfolio
About G1 Therapeutics, Inc.
- Ticker GTHX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 42,746,800
- Market Cap $306M
- Description
- G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/...